Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs InMode Ltd — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $90.97 (market cap $12.79B), while InMode Ltd trades at $14.07 (market cap $806.05M). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is far larger — about 15.9× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and InMode Ltd for 29 Days on average.
| EMB | INMD | |
|---|---|---|
Market Cap | $12.79B | $806.05M |
Volume | 8,552,536 | 511,446 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $16.62 |
52-Week Low | $90.14 | $12.76 |
Typical Hold Time | 50 Days | 29 Days |
Enterprise Value | — | $309.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows mixed momentum with RSI indicators suggesting potential oversold conditions at lower timeframes. Recent corporate actions include scheduled dividend payments through late 2026, though key valuation and profitability metrics remain unavailable for analysis.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment appeal may center on future dividend income given the lack of current fundamental data. Primary risks include market volatility and the absence of transparent financial metrics for proper valuation assessment.
INMD trades at $14.01, showing minimal daily movement with a 0.14% gain. The stock faces bearish technical signals despite attractive valuation metrics including a P/E of 11.58 and EV/EBITDA of 4.43. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while the company faces shareholder activism from Steel Partners' $16.75 per share acquisition offer. Revenue guidance for 2026 remains stable at $365M-$375M.
The investment case balances strong profitability margins against technical weakness and activist pressure. With 45% analyst buy ratings and no sell recommendations, fundamental value appears intact, but near-term price action suggests caution. Key catalysts include Q3 2026 earnings and resolution of the acquisition proposal, while risks include execution challenges and macroeconomic headwinds affecting aesthetic medicine demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
